The Food and Drug Administration announced on April 14 new draft guidance aimed at gene editors, especially those using next-generation sequencing to detect unintended effects in certain gene therapies.
The FDA said the goal is to standardize safety evaluations for genome editing treatments, which could help speed up the development of novel therapies, including personalized options for ultra-rare diseases. The guidance was issued by the agency’s Center for Biologics Evaluation and Research and builds upon earlier recommendations from early 2024 that addressed human genome editing tools. It covers both ex vivo and in vivo products.
According to the FDA, these recommendations are meant to support nonclinical studies submitted with investigational new drug applications or biologics license applications. They include suggestions related to sequencing strategies, sample selection, and analysis parameters.
“We’re giving sponsors a roadmap for comprehensive safety assessment while supporting the efficient development of these promising therapies,” outgoing CBER Director Vinay Prasad said in a statement Tuesday. “Our goal is to work collaboratively with the scientific community to bring safe and effective genome editing therapies to patients who need them most,” Prasad added. He will be leaving his position at the end of this month after what has been described as a controversial tenure with the regulator.
FDA Commissioner Marty Makary also commented on Tuesday’s announcement: “Genome editing holds extraordinary promise for treating previously incurable genetic diseases, and today’s announcement represents the FDA’s forward approach to drive innovation and advance the development of genome editing therapies.” Makary continued, “This guidance provides sponsors with clear, scientifically-grounded recommendations for evaluating off-target editing risks using state-of-the-art sequencing technologies. We are serious about moving this ball forward.”
The agency is currently seeking public comment on its draft guidelines. This move follows a February announcement regarding a new pathway designed specifically to accelerate bespoke therapy development for ultra-rare diseases—a framework inspired by creating a custom CRISPR therapy for baby KJ, who was born with a rare metabolic disorder.
While introducing this new approach for individualized treatments, recent decisions by regulators concerning rare disease cases have drawn criticism from some stakeholders over perceived inconsistencies compared with previous feedback from the FDA.
